GBLX - GB Sciences, Inc.

GB Sciences, Inc.

3550 West Teco Avenue
Las Vegas, NV 89118
United States
866-721-0297
http://gbsciences.com

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 56

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. John C. Poss	Chairman & CEO	341.03k	N/A	1948
Ms. Ksenia Griswold	COO, CFO, VP & Controller	226.15k	N/A	1983
Dr. Andrea Small-Howard M.B.A., Ph.D., MBA	Member of Scientific Advisory Board, Chief Science Officer & Director	135.38k	N/A	1969
Mr. Krin Ellery Kuethe	Sr. VP of Cultivation	471.18k	N/A	1984
Mr. John B. Davis	Gen. Counsel, Exec. VP & Corp. Sec.	N/A	N/A	N/A

Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GB Sciences, Inc. focuses to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for various ailments. It is developing technologies in plant biology, cultivation and extraction techniques, which are combined with biotechnology; and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

Corporate Governance

GB Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.